Markets › United States › NAS › KLRA

Kailera Therapeutics Inc

NAS:KLRAHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$12.89+12.77%At closeAt close · Wed 21 Oct · ≈ AED 47.34 · Market cap $1.67B · Next earnings Wed 2 Dec

USD millions	FY2024	FY2025
Revenue	0.0	0.0
Cost of revenue	0.1	0.0
Gross profit	(0.1)	0.0
Research & development	7.0	109.1
Selling, general & administrative	—	49.2
Selling & marketing	—	0.0
Operating expenses	16.3	158.3
Operating income	(16.3)	(158.3)
Interest expense	0.0	0.0
Interest income	2.5	11.0
Other income / expense	—	9.4
Pre-tax income	(219.7)	(149.0)
Income tax	0.0	0.0
Net income	(219.7)	(149.0)
Discontinued operations	—	0.0
Other net income adjustments	—	0.0
EPS, basic (per share)	(2.60)	(1.26)
EPS, diluted (per share)	(2.60)	(1.26)
EBITDA	(16.3)	(158.0)
Depreciation & amortization	0.1	0.3
Weighted average shares (shares)	84,615,439	117,948,773
Weighted average diluted shares (shares)	84,615,439	117,948,773